Revolution Medicines shares promising data around KRAS drug combination
Revolution Medicines has released promising Phase 1/2 clinical data for a KRAS drug combination targeting metastatic pancreatic cancer.
📍 How it ended
Revolution Medicines presented Phase 1/2 clinical data for Zoldonrasib combination regimens for patients with RAS G12D metastatic pancreatic cancer at the ESMO Gastrointestinal Cancers Congress 2026. The company shared promising data regarding the KRAS drug combination.
Epilogue added 42d ago, after coverage quieted.
Coverage (5)
- Anirban Maitra։ Data on Zoldonrasib Plus Daraxonrasib in 2nd and 3rd Line Metastatic Pancreatic Cancer Oncodaily · 46d ago
- Practice-Changing Data in GI Oncology Medscape · 46d ago
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Yahoo Finance · 46d ago
- Experimental cancer drug brings time and hope for patients WSAW · 46d ago
- Revolution Medicines shares promising data around KRAS drug combination Endpoints News · 46d ago broke it first
What happened
Revolution Medicines presented Phase 1/2 clinical data at the ESMO Gastrointestinal Cancers Congress 2026. The results focus on Zoldonrasib combination regimens, specifically Zoldonrasib plus Daraxonrasib, for patients with RAS G12D metastatic pancreatic cancer in 2nd and 3rd line settings.
Coverage from Endpoints News, Yahoo Finance, and Oncodaily highlights the promising nature of the data. Medscape describes the findings as practice-changing for GI oncology, while WSAW notes the experimental drug provides additional time and hope for patients.
Future developments center on the application of these combination regimens within gastrointestinal oncology and the progression of the experimental drug's clinical timeline.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 45d ago.
Questions people are asking
What specific cancer is being targeted?
The data focuses on patients with RAS G12D metastatic pancreatic cancer.
Which drugs are being used in the combination?
The combination involves Zoldonrasib and Daraxonrasib.
Where was this data presented?
The data was presented at the ESMO Gastrointestinal Cancers Congress 2026.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
Related trends
Pancreatic cancer vaccine shows promise in first human trial, preventing disease in high-risk patients
A first-in-human clinical trial for a mutant KRAS vaccine shows promise in preventing pancreatic cancer among high-risk patients.
Johns Hopkins surgeon highlights AI breakthrough that could spot pancreatic cancer before doctors
Healthcare leaders are balancing the integration of advanced AI diagnostic tools with the necessity of maintaining human-centric patient care.
Only 13% survive this cancer. A blood test just detected 90% of early cases
A new blood gene test has demonstrated the ability to detect 90% of early-stage pancreatic cancers, a disease with a 13% survival rate.
Pancreatic cancer breakthrough has big implications for early detection effort - San Diego Union-Tribune
Experimental cancer treatment Daraxonrasib is gaining momentum as regulators fast-track review and clinical data suggests potential advancements in patient care.
Grand Rapids oncologist says experimental pancreatic cancer drug showing promise in trials offers hope
An experimental drug targeting pancreatic cancer is showing promising survival gains in clinical trials.